Try our mobile app

Published: 2021-05-04 11:31:27 ET
<<<  go to PETS company page
EX-99.1 2 ex_246393.htm EXHIBIT 99.1 ex_246393.htm

Exhibit 99.1

 

 

PETMED EXPRESS, INC. D/B/A 1-800-PETMEDS ANNOUNCES ITS FOURTH QUARTER AND FISCAL YEAR END FINANCIAL RESULTS AND INCREASES ITS QUARTERLY DIVIDEND TO $0.30 PER SHARE

 

8.8% Increase in Fiscal 2021 Sales

18.4% Increase in Fiscal 2021 Net Income

9.7% Increase in Fiscal 2021 Reorder Sales

 

Delray Beach, Florida, May 3, 2021 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for its fourth quarter and fiscal year ended March 31, 2021. Net sales for the year ended March 31, 2021 were $309.2 million, compared to $284.1 million for the year ended March 31, 2020, an increase of 8.8%. Net income for the year ended March 31, 2021 was $30.6 million, or $1.52 diluted per share, compared to net income of $25.9 million, or $1.29 diluted per share, for the prior year, an increase to net income of 18.4%. Reorder sales for the year ended March 31, 2021 were $272.6 million, compared to $248.6 million for the year ended March 31, 2020, an increase of 9.7%. New order sales for the year ended March 31, 2021 were $36.6 million, compared to $35.6 million for the year ended March 31, 2020, an increase of 2.8%. The Company acquired approximately 443,000 new customers in the year ended March 31, 2021, compared to 421,000 new customers in the prior year. The average order size for the year ended March 31, 2021 was $89, compared to $87 for the year ended March 31, 2020. Net sales for the quarter ended March 31, 2021 were $71.7 million, compared to $74.3 million for the quarter ended March 31, 2020, a decrease of 3.5%. Net income for the quarter ended March 31, 2021 was $6.8 million, or $0.34 diluted per share, compared to net income of $7.0 million, or $0.35 diluted per share, for the same quarter the prior year, a decrease to net income of 2.7%. The average order size for the quarter ended March 31, 2021 was $93, compared to $90 for the quarter ended March 31, 2020.

 

Menderes Akdag, President and CEO, commented: “Overall we were pleased with our fiscal 2021 results with increases to both our top and bottom line. The year started out with greater than expected ecommerce demand due to COVID-19, with consumers shifting their purchases to online, which positively impacted our sales for the year, then in the back half of fiscal 2021, veterinarian clinics and retail stores re-opened. Our bottom line was positively impacted by growth in our gross margins by 50 basis points, due to having direct relationships with the major manufacturers, and with our operating expenses decreasing by 76 basis points, which resulted in a 126 basis points improvement to our operating income. Cash from operations increased to $40.1 million in fiscal 2021, compared to $38.8 million in fiscal 2020. In the quarter ended March 31, 2021 the reduction to sales and net income were possibly related to a pull forward of demand in the prior year due to the pandemic, along with colder weather during the March quarter, which might have delayed the start of flea and tick season. In fiscal 2022, we will be exploring alternative ways of acquiring new customers and adding value-added services, and we will continue investing in our e-commerce platform and mobile app to optimize our customers’ digital experience.”

 

The Board of Directors declared an increased quarterly dividend from $0.28 to $0.30 per share on its common stock. The dividend will be payable on May 21, 2021, to shareholders of record at the close of business on May 14, 2021. The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance. This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the year-end financial results. To access the call which is open to the public, dial (888) 455-1758 (toll free) or (203) 827-7025. Please call in fifteen minutes prior to the scheduled start time. Callers will be required to supply PETMEDS as the passcode. For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. Eastern Time on May 3, 2021 until May 17, 2021 at 11:59 P.M. Eastern Time. To access the replay, call (800) 860-4709 (toll free) or (203) 369-3837 and enter passcode 5500.

 

Founded in 1996, PetMed Express is America’s Most Trusted Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs, cats, and horses at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com. This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such “forward-looking” statements are set forth in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2020. The Company’s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K. For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444.

 

 

###

 

Exhibit 99.1 Page 1 of 4

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except for per share amounts)

 

   

March 31,

   

March 31,

 
   

2021

   

2020

 

 

 

(UNAUDITED)

         
ASSETS                
                 

Current assets:

               

Cash and cash equivalents

  $ 118,718     $ 103,762  

Accounts receivable, less allowance for doubtful accounts of $39 and $59, respectively

    2,587       3,843  

Inventories - finished goods

    34,420       17,884  

Prepaid expenses and other current assets

    4,503       3,529  

Prepaid income taxes

    959       -  

Total current assets

    161,187       129,018  
                 

Noncurrent assets:

               

Property and equipment, net

    25,450       25,445  

Intangible assets

    860       860  

Total noncurrent assets

    26,310       26,305  
                 

Total assets

  $ 187,497     $ 155,323  
                 

LIABILITIES AND SHAREHOLDERS' EQUITY

               
                 

Current liabilities:

               

Accounts payable

  $ 39,548     $ 19,658  

Accrued expenses and other current liabilities

    5,387       4,214  

Income taxes payable

    -       471  

Total current liabilities

    44,935       24,343  
                 

Deferred tax liabilities

    1,281       970  
                 

Total liabilities

    46,216       25,313  
                 

Commitments and contingencies

               
                 

Shareholders' equity:

               

Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share

    9       9  

Common stock, $.001 par value, 40,000 shares authorized; 20,269 and 20,166 shares issued and outstanding, respectively

    20       20  

Additional paid-in capital

    7,111       3,804  

Retained earnings

    134,141       126,177  
                 

Total shareholders' equity

    141,281       130,010  
                 

Total liabilities and shareholders' equity

  $ 187,497     $ 155,323  

 

Exhibit 99.1 Page 2 of 4

 

PETMED EXPRESS, INC. AND SUBSIDIARIES 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 

(In thousands, except for per share amount) 

 

   

Three Months Ended

   

Year Ended

 
   

March 31,

   

March 31,

 
   

2021

   

2020

   

2021

   

2020

 
   

(UNAUDITED)

   

(UNAUDITED)

         

Sales

  $ 71,679     $ 74,286     $ 309,215     $ 284,125  

Cost of sales

    51,157       52,600       219,267       202,879  
                                 

Gross profit

    20,522       21,686       89,948       81,246  
                                 

Operating expenses:

                               

General and administrative

    7,243       6,413       28,293       25,264  

Advertising

    4,256       6,205       21,641       22,748  

Depreciation

    636       555       2,427       2,257  

Total operating expenses

    12,135       13,173       52,361       50,269  
                                 

Income from operations

    8,387       8,513       37,587       30,977  
                                 

Other income:

                               

Interest income, net

    85       300       314       1,747  

Other, net

    377       307       1,315       1,169  

Total other income

    462       607       1,629       2,916  
                                 

Income before provision for income taxes

    8,849       9,120       39,216       33,893  
                                 

Provision for income taxes

    2,037       2,117       8,613       8,042  
                                 

Net income

  $ 6,812     $ 7,003     $ 30,603     $ 25,851  
                                 

Net income per common share:

                               

Basic

  $ 0.34     $ 0.35     $ 1.53     $ 1.29  

Diluted

  $ 0.34     $ 0.35     $ 1.52     $ 1.29  
                                 

Weighted average number of common shares outstanding:

                         

Basic

    20,100       19,984       20,060       20,041  

Diluted

    20,177       20,010       20,119       20,055  
                                 

Cash dividends declared per common share

  $ 0.28     $ 0.27     $ 1.12     $ 1.08  

 

Exhibit 99.1 Page 3 of 4

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

   

Year Ended

 
   

March 31,

 
   

2021

   

2020

 
   

(UNAUDITED)

         

Cash flows from operating activities:

               

Net income

  $ 30,603     $ 25,851  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation

    2,427       2,257  

Share based compensation

    3,307       2,822  

Deferred income taxes

    311       (151 )

Bad debt expense

    130       191  

(Increase) decrease in operating assets and increase (decrease) in liabilities:

               

Accounts receivable

    1,126       (1,492 )

Inventories - finished goods

    (16,536 )     3,486  

Prepaid income taxes

    (959 )     582  

Prepaid expenses and other current assets

    (974 )     (376 )

Accounts payable

    19,890       3,383  

Accrued expenses and other current liabilities

    1,221       1,820  

Income taxes payable

    (471 )     471  

Net cash provided by operating activities

    40,075       38,844  
                 

Cash flows from investing activities:

               

Purchases of property and equipment

    (2,432 )     (2,311 )

Net cash used in investing activities

    (2,432 )     (2,311 )
                 

Cash flows from financing activities:

               

Dividends paid

    (22,687 )     (21,803 )

Repurchase and retirement of common stock

    -       (11,497 )

Net cash used in financing activities

    (22,687 )     (33,300 )
                 

Net increase in cash and cash equivalents

    14,956       3,233  
                 

Cash and cash equivalents, at beginning of year

    103,762       100,529  
                 

Cash and cash equivalents, at end of year

  $ 118,718     $ 103,762  
                 

Supplemental disclosure of cash flow information:

               
                 

Cash paid for income taxes

  $ 10,018     $ 7,140  
                 

Property and equipment in current assets

  $ -     $ 1,745  
                 

Dividends payable in accrued expenses

  $ 198     $ 246  

 

 

Exhibit 99.1 Page 4 of 4